Market capitalization | $1.38b |
Enterprise Value | $1.31b |
P/E (TTM) P/E ratio | 16.10 |
EV/FCF (TTM) EV/FCF | 24.02 |
EV/Sales (TTM) EV/Sales | 3.83 |
P/S ratio (TTM) P/S ratio | 4.04 |
P/B ratio (TTM) P/B ratio | 7.65 |
Revenue growth (TTM) Revenue growth | 10.93% |
Revenue (TTM) Revenue | $342.81m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a MiMedx Group, Inc. forecast:
5 Analysts have issued a MiMedx Group, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 343 343 |
11%
11%
|
|
Gross Profit | 285 285 |
13%
13%
|
|
EBITDA | 67 67 |
245%
245%
|
EBIT (Operating Income) EBIT | 64 64 |
331%
331%
|
Net Profit | 88 88 |
1,938%
1,938%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.
Head office | United States |
CEO | Joe Capper |
Employees | 895 |
Founded | 1985 |
Website | www.mimedx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.